Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Quick links
Contact us
PO Box 3787

South Brisbane QLD 4101
Become a patient

Dr Kerry Cheong

MBBS(Hons), FRACP

  • Medical Oncologist
Become a patient Refer a patient
Adelaide
08 8474 0220 08 8450 3375
admin.adelaide@icon.team

Biography

Dr Kerry Cheong is a medical oncologist at Icon Cancer Centre Adelaide. She attended Flinders University where she obtained a Bachelor of Medicine and Bachelor of Surgery (MBBS) with honours and completed specialist oncology training at London’s Guy’s Hospital, London.

Whilst in London she was involved in phase II trials of new drugs and research in quality of life and geriatric oncology. Dr Cheong has worked full-time at the Icon Cancer Centre Adelaide since joining the team in March 2005. Her clinical experience covers a broad range of solid tumour malignancies with special clinical interest in breast cancer, lung cancer and gastrointestinal cancer.

Research

Trials being conducted by this doctor

ELEGANT / STML-ELA-0422

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

Locations Southport, Wesley, Townsville, Hobart, Adelaide

Diagnosis Breast cancer

Open for recruitment

C4551002

The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells.HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2-negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface.Advanced cancer is a term that is often used to describe cancer that is unlikely to be cured. Metastatic cancer is the type where the cancer cells spread from one part of the body to another.This study is seeking for participants whose breast cancer has gotten worsen after receiving cyclin dependent kinase (CDK) 4/6 inhibitor-based therapy. Half of participants in this study will receive their usual study treatment, everolimus with endocrine therapy (either exemestane or fulvestrant) for HR-positive/HER2-negative advanced or metastatic breast cancer (A/mBC). The study doctor will discuss which hormone therapy is right for the participant before treatment begins. PF-07248144 is a tablet that will be taken by mouth at home every day in a 28-day cycle. Fulvestrant will be given as two injections (one injection in the buttock) at visits to the study clinic. Everolimus and exemestane are also tablets and will be taken by mouth at home every day in a 28-day cycle.The study will compare the experiences of people receiving PF-07248144 in combination with fulvestrant to those of the people who do not. This will help see if PF-07248144 in combination with fulvestrant is safe and effective.

Locations Adelaide

Diagnosis Breast cancer

Open for recruitment